Compare HCAT & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | SGMO |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.0M | 155.1M |
| IPO Year | 2019 | 2000 |
| Metric | HCAT | SGMO |
|---|---|---|
| Price | $2.72 | $0.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 7 |
| Target Price | $4.30 | ★ $4.71 |
| AVG Volume (30 Days) | 858.1K | ★ 9.6M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $316,063,000.00 | $32,875,000.00 |
| Revenue This Year | $3.23 | $28.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.63 | N/A |
| 52 Week Low | $2.02 | $0.38 |
| 52 Week High | $8.91 | $2.84 |
| Indicator | HCAT | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 52.17 |
| Support Level | $2.02 | $0.42 |
| Resistance Level | $3.03 | $0.48 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 69.80 | 67.00 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.